CYP2D6 polymorphism in patients with eating disorders

Pharmacogenomics J. 2012 Apr;12(2):173-5. doi: 10.1038/tpj.2010.78. Epub 2010 Sep 28.


CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is, serotonin), personality, neurocognition and psychopathology. The relationship between CYP2D6 genetic polymorphism and the risk of eating disorders (ED) was analyzed in 267 patients with ED and in 285 controls. A difference in the CYP2D6 active allele distribution was found between these groups. Women carrying more than two active genes (ultrarapid metabolizers) (7.5 vs 4.6%) or two (67 vs 58.9%) active genes were more frequent among patients with ED, whereas those with one (20.6 vs 30.2%) or zero active genes (4.9 vs 6.3%) were more frequent among controls (P<0.05). Although further research is needed, present findings suggest an association between CYP2D6 and ED. CYP2D6 allele distribution in patients with ED seems related to increased enzyme activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Alleles
  • Case-Control Studies
  • Cytochrome P-450 CYP2D6 / genetics*
  • Feeding and Eating Disorders / genetics*
  • Female
  • Humans
  • Middle Aged
  • Polymorphism, Genetic*
  • Young Adult


  • Cytochrome P-450 CYP2D6